Drugscience Ltd
la company Ilmlted by guarantee)
Annual report and financial statements
For the year ended 30 lune 2022
Registered company number.. 08032149
Registered charity number.. 1150449

DruBscience Ltd
Contents
Page
Reference and administrative details
Trustees. report
2-13
Independent examinerfs report
14
Statement of financial activities
15-16
Statement of financial position
17
Notes to the financial statements
18-25

Drugscience Ltd
Reference and administrative details
For the year ended 30June 2022
Trustees
S Macken
Prof Ilana Crome- Chair
C G Hughes (appointed on 15 August 20221
D E A5hley-Cooper (appointed on 15 August 20221
A D Knight
Prof D Nutt
J Smith
Secretary
S P Macken
Company registered number
08032149
Charltyreglstered number
1150449
Re8lStered office
130 Wood Street
London
EC2V 6DL
Independent examiner
Buzzacott LLP
130 Wood Street
London
EC2V 6DL

Drugscience Ltd
Trusteeg report
For the year ended 30 June 2022
The trustees present their annual report together with the financial statements of Drugscience Ltd I'the charity'l for the year
ended 30 June 2022.
STRucfuRE. GOVERNANCE AND MANAGEMENT
Constitution
The charity is constituted under a Memorandum of Association dated 16 April 2012 and amended by a Special Resolution
dated 17 December 2012. It is a registered charity with its charity number being 1150449.
The charity is limited by guarantee and doe5 not have share capital. All trustees are members of the charity and guarantee to
contribute £1 in the event of winding up.
Appolntment of trustees
The trustees have complete control of the charity in relation to the application of funds. Trustees are appointed in accordance
with the charity's governing document. All decision-making of Drugscience is made in accordance with the charity's Conflicts of
Interest policy.
Trustees
The trustees who served during the year were..
S Macken
Prof Ilana Crome
C G Hughes lappointed on 15 August 20221
D E Ashley-cooper (appointed on 15 August 20221
A D Knight
Prof D Nutt
I Smith
OBJECTIVES AND ACTIVITIES
Policies and objectives
The principal objectives of the charity are=
to advance the education of the public in the harms of drug taking to help prevent and mitigate the sufferin8 caused
by drug harms and a550ciated behaviour5-
to promote the Eood health of the general public by providing advice to the public and practitioners who are impacted
by drug taking in anyway,. and
to promote research for the benefit of the public, in the subject of drugs and drug taking and into its effects on the
public and society in general, whether physical, medical, psychological or social.
Public benefit Statement
The trustees have given due consideration the Charity Commission published guidance on the public benefit requirements. The
charity constitutes a public benefit entity as defined by FRS 102.

Drugscience Ltd
Trustee< report (continued)
For the year ended 30 lune 2022
ACHIEVEMENTS AND PERFORMANCE
The charity has a vital role to play in society, providing the public in the UK and internationally with high quality, scientifically
based information on drugs and evidence-based comment and analysis of new research. The charity aims to inform public
understanding about drugs and promote effective policies and practice in the UK and at international level.
The charity reviews and investigates the scientific evidence relating to dru85, free from political concern5. The charity
provides accessible information on drugs to the public and professionals via direct communication, podcasts, educational
resources, webinars, events and via its web-based information pages. The charity works in the UK and internationally and
addresses issues surrounding drug harms and benefits,. regulation and education., prevention, treatment and recovery.
We believe that..
Everyone has the right to be able to access accurate information about the effects, harms and benefits of drugs.
All people have the right to receive effettive, evidence-based drug education.
All people with drug-related problems have the right to services that will support their recovery.
There needs to be an ongoing and open public discussion about drugs and their place within our society.
Policy and practice should be based on evidence from research and experience and independent review.
All drug users have the right to a life free from discrimination and stigma.
Any regulation of druÈ use should aim to prevent and reduce the harmful consequences of drug use. It should be
proportionate to the harm5.
It is vitally important to extend the evidence base on drugs through research.
Public services should aim to prevent and reduce harms to drug users and others.
Unnete55ary and overly laboriou5 barriers to research should be eroded to facilitate a higher quality understanding of
drug5 regardless of their legal 5tatU5.
Trustee meetin
The charity trustee meetinEs were held every three months throughout this period. The main issues discussed included-.
Governance and organi5ational structure
Fundraising
Drug Science strategy
Updating of trustees
Updating on present expert members
The importance of tontinuing regular newsletters
Reports
Research progress
General
In the last period, the charity has continued to grow in terrns of g8nerated incorne, the staff team, the charity's research
outputs, and its contributions to policy making and public communications. Total income received during the financial year
has been the highest ever achieved since we were founded over 10 years ago, including a major donation to further the work
of the organisation.

Drugscience Ltd
Trustee< report (continued)
For the year ended 30 lune 2022
Drug Science has incorporated a trading Subsidiary, called Drug Science Tradin8 Ltd. The purpose of the subsidiary is the
provision of a consultancy service to commercial stakeholders in the areas of medical cannabis and psychedelic research. The
subsidiary is a registered company wholly owned by Drug Science, donating IOOYO of its surplus to the charity.
The charity Is now leading four working groups.. the Medical Cannabis Working Group IMCWGI, the Medical Psychedelic5
Working Group IMPWGI the Enhanced Harm Reduction Working Group IEHRWGI and the Education Working Group IEWGI
Isee further details belowl.
All of this work is made possible through the great contributions made by expert rnember volunteers. We are grateful for the
many hour5, member5 have worked on p3rticipating and presenting at the quarterly Drug Science 5ymp05ia, writing public
letters, reports and publishing relevant papers. Without this valuable contribution of time, energy and expertise the charity
would not have been able to achieve so much. Throughout this period, the Drug Science Scientific Committee continued to
meet every three months to discuss possible outputs from the charity and other interrelated issues that are relevant to the
charity.
General research outputs
DSPL journal- change in publishing group has improved turnover rates recently IPublications available..
htt
ournals.sa
ub.com
home
Discu55ion were held with publishers on how best to dev8lop the journal,
and work towards Impact Factor. Special Issue on Ayahuasca (led by Dr Simon Ruffelll currently in preparation.
Crome, l. Nutt, D, Steven5, A. leds.I120221. Drug Science and British Drug Policy. Waterside Press.
Ferreira, P.M., Nutt D.120221. Regulating the oxides of nitrogen- popping the myths. DSPL,. 8.
Ferreira. P.M.. Winstock,A.R. Schlag, A.K., et al.120221 A comparative study of the harms of nitrous oxide and
poppers usin8 the MCDA approach. DSPL.. 8.
Policy contributions include response to white paper 'Swift, certain. touÈh.. new consequences for drug possession,
www.
ov.uk
overnment
consultations
5wift-certain-tou
-new-con5e
uence5-for-dru
ossession-white-
erl, together with large Scale signature collection together with Release, Transform, International Drug Policy
Consortium, Centre for Justice Innovation
Contribution to TGA rescheduling of MDMA and Psilocybin in Australia. David Nutt and the Drug Science team
prepared in-depth report to support Mind medicine
Invited conferences include.. European Sceptics (Viennal.. Oxford Literary Festival,. BNA Festival DruÉ Science
Symposium (Brightonl,. We our here Festival St Gile5 IDor5etl
Medical Cannabis Workin
Grou
MCWG
The Medical Cannabi5 Working Group is a cro55-sertor collaboration that includes scientific expert5, academic5, policy makers
and leaders of patient advocacy groups alongside industry partners collectively aiming to improve and accelerate access of
medical cannabis in the UK for all patients.
Aim
To improve and accelerate access of medical cannabis in the UK for all patients.
Objectives
Develop and deliver scientific research on medical cannabis
Ensure provision of education and training for physicians and health care professionals
Improve evidence base through Real World Data collection
Ensure effective communication between stakeholders, involving patients and addressing patients concerns
Address stigma within the medical profession, media and the general pubic
Advocate for transparency across industry relationships
The Medical Cannabis Working Group is a collaboration that continues to prioritise an approach that includes..

Drugscience Ltd
Trustee< report (continued)
For the year ended 30 lune 2022
lil Medical education,
lill Reasonable access to patients in need and patients seeking medical cannabis, along with
liiil The collection of robust real-world data that may inform effectiveness and safety, along with QALY and patient reported
outcomes.
These approaches are key in the implementation of an effective access programme in the UK that is most likely to have the
best public health outcome.
It is clear that whi15t there is great progre55 in access to medical cannabis being made worldwide, patient5 in the UK are being
prevented from acce55ing potentially beneficial treatment, de5Plte cannabi5 having been legally cla55ified as a rnedicine since
November 2018. Since then, only a handful of patients have received a prescription on the NHS, despite lobby and patient
groups suggesting the number of patients currently using illicit cannabis for therapeutic purposes in the UK to be in the
region of 1.4 million people.
We believe that a balance must be struck between the access demands of patients based on unmet need, the risk of a
burgeoning illicit market in the context of restricted access, and the collection of data to monitor safety. Medical cannabis is
already being made available in significant numbers in Europe and in other countries, whilst patients in the UK are being
driven to the illicit cannabis market characterised by irregular products hiEh in THC, or the CBD market currently governed as
a novel food by the Food Standards A@encv
Research out uts of the MCWG
Launch of health economics analysis on medical Cannabis and chronic pain in Feb 2023, together with the Cannabis
Industry Council. Estimated completion by end of April 2023 Drug Science will lead the peer reviewed publication.
Launch of paediatric epilepsy study using specifically developed app (by AltaFloral to develop our previous work in this
area, in March 2023.
Sunderland, P, Schlag AK, Nutt, D. Medication sparing after medical cannabis initiation.. A case study of a chronic pain
patient in Project Twenty21. DSPL (ln Press)
Lyn5key MT, Schlag AK, Athanasiou-Fiagkouli A, Badcock D, Nutt DJ. Characteristics of and three-month health
outcomes for people seeking treatment with prescribed cannabi5.' Real World evidence frorn Project Twenty 21. DSPL
Iln Press)
O'Brien K, Belby I, Frans M, Lynskey M, et al. Preliminary Findings from Project Twenty21 Australia.. an Observational
Study of Patients.. Prescribed Medicinal Cannabis for Chronic Pain, Anxiety. PTSD and Multiple Sclerosis. DSPL Iunder
Review)
Thurgur, H, Schla& AK, et al. Medical cannabis and Long Covid.. Current uses and potential future applications.
Exploration of Medicine.. Sl Beyond Weed (Under Reviewl
Schla8 AK, Zafar RR, Lynskey MT, Athanasiou-Fra8kouli A, Phillip5 LD and Nutt DJ120221 The value of real world
evidence.. The case of medical cannabis. Front. Psychiatry 13.'1027159.
htt
www.frontiersin.or
10.3389
t.2022.1027159
Zafar R, Sulak D, 8rambila J, Nutt D. Schlag A.K.120221. Raising awareness.. The implementation of medical cannabis
and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer. DSPL.,
8. htt
ourn315.sa
ub.com
doi
10.1177
20503245221114323
Bourke S., Schlag, A.K., O'sullivan, S., Nutt, D., Finn, D. Cannabinoids and the endocannabinoid system in fibromyalgia..
A review of preclinical and clinical research. Pharmacology and Therapeutics. DOI.. 10.1016
harmthera.2022.108216
Schlag, A.K. Lynskey, M., Fayez, A. et al. Characteristics of people seeking prescribed cannabinoids for the treatment of
chronic pain.. Evidence frtsm Project Twenty 21. Frontiers.. Medical Cannabis and Pain.
doi.or
10.3389
ain.2022.891498
Invited conferences include.. Medicinal Cannabis Summit (Berlinl.. CT Cann ICopenhagenl- CT Cann Trials ILondonl-
Cannabis Europa (London)
Various invited webinars, e.g., Romanian Parliament; Constellations, Analytical Cannabis

Drugscience Ltd
Trustees, report (continued)
For the year ended 30 lune 2022
Pro
ect Twent 21
Pro
ect Twent 21 is Europe's largest real-world data registry to document efficacy. safety, quality-adjusted life year, and
patient reported outcomes in prescribed medical cannabis in the UK.
Through Project Twenty21, eligible patients can access affordable medical cannabis treatment, monitored by Drug Science.
The project aims to create the largest body of evidence for the effectiveness and tolerability of medical cannabis. The findings
of Project Twenty21 will provide evidence for NHS funding if the benefits of treatment with medicinal cannabis is proven to
outweigh the potential risks.
At the start of the year, we officially renamed the project 'T21" to coincide with a new phase of the study, as we welcomed
new partners and announced a new pricing discount model whereby patients can obtain a minimum of 5Yo off products listed
on our formulary.
The initial partner contracts for T21 all expired at the end of last year lacross November and December 20221. These
contracts covered the initial 3 year phase of the project, and contributed £1.6m to delivery during this period. The project has
so far made a si8nificant impact on the medical cannabis sector, putting Drug Science at the very forefront of research and
health outcome data in the UK. With wide interest from all stakeholder5 to continue the project, Drug Science ha5 been able
to successfully negotiate new contracts with all but one of the legacy partners (Khiron, Leva and JMCC Gropupl, as well as
agree three new partnerships with Licensed producers IEthypharm, Spectrum Canopy and Grow Pharmal. A5 the project has
become firmly established, the'start up. costs associated with the first phase are no longer a requirement, and therefore the
amount required from each partner has been reduced.
The Australian arm of T21 (led by Releaf Group) continues for another year and is on track to complete by December 2023.
Initial data analysis from Australia remains consistent from the considerable data now collected in the UK. further supporting
the effectiveness and tolerability if medical cannabis generally.
Lon
The Long COVID clinical trial was sponsored by Bod Healthcare with Drug Science acting as an investigator site who
contracted Dr Elizabeth Iveson as Principal Investigator IPII. The LonE COVID clinical trial was granted approval from the NHS
Research Ethics Committee INHS RECI and Medicines and Healthcare products Regulatory agency IMHRAI in January 2022.
The first participant was enrolled in April 2022 and the end of study was declared on 6" January 2023 INHS REC and MHRA
notified on 17, January 20231. A total of 12 participants were enrolled.
The MHRA conducted a Good Clinical Practice IGCPI inspection of the trial on the week commencing 3 October 2022. There
were 2 Critical finding5 (along with Several major and minor finding51 identified during the in5PeCtion relating to Clinical Trial
Authorisation and Investigational Medicinal Product IIMPI. Critically, the IMP supply issues couldn't be resolved, and the
clinical trial wa5 terminated early.
The data from the trial is currently being analysed by the study team at Orug Science and will be published in a peer reviewed
journal. The clinical trial was a valuable learning experience for Drug Science and highlighted the need for a new approach if
Drug Science are involved in future clinical trials. Critically, new strategies would involve input from clinical trial and
regulatory experts.
Medical Ps thedelics Workin
Grou
The Medical Psychedelics Working Group is a cross-sector collaboration that includes scientific experts, academics,
policymakers, leaders of patient advocacy 8roups and industry representatives, collectively aiming to create a rational and
enlightened approach to psychedelic research and clinical treatment. To create a rational and enlightened approach to
psychedelic research and clinical treatment.

Drugscience Ltd
Trustee< report (continued)
For the year ended 30 lune 2022
Aim
To create a rational and enlightened approach to psychedelic research and clinical treatment
Ob'ective5
Develop and deliver scientific research on psychedelic drugs
Provide evidence that supports the removal of psychedelic drugs from Schedule I restrictions
Work with regulatory bodies to ensure that relevant legislation is enacted to facilitate medical use of psychedelic
drugs
Promote destigmatisation and improved understandin8 of psychedelic drug5
Provide evidence-based educational resources on psychedelic medicine for doctors, pharmacists, healthcare
professionals and the general public
We believe that the future of psychedelic medicine is extremely promising, and there is potential for the widespread
application of psychedelic dru8S Wlthin public health mode15. After witnessing the le8ali5ation of medical cannabi5 in 2018,
we recognised a need to work collaboratively and proactively with interdisciplinary partners to ensure that psychedelic
medicines are developed for UK. EU and worldwide healthcare models.
Current regulations have created seriou5 and considerable barriers to legitirnate research asSOClated with schedule I
re8ulation5. While existing legislation doe5 not preclude scientific research with these drugs, it does make studies
considerably more difficult, time-consuming and costly.
With further research and a greater understanding amongst policy maker5, acadernics, the media and the general public,
there is a realistic prospect of regulatory approval for psychedelic medicines. We aim to ensure that medical psychedelic5
can be used safely in an ethical and economically sustainable manner and demonstrate a potential for lasting therapeutic
benefit.
In 2020, we decided to establish the Medic31 Psychedelic5 Working Group to break down the barrier5 of 50 years of rnedical
censorship by creating a rational and enlightened approach to psychedelic research and clinical treatment. The group
explores innovation within the psychedelic space with a specific focus on how psychedelics can be integrated into primary
and secondary healthcare. Our belief is that evidence-based science, data sharing, and strong partnerships are essential for
the success of psychedelic medicines.
Research out uts of the MPWG
Schlag, A.K. Aday, J. Salam, l.. Neill, J., Nutt, D.120221. Adverse effects of psychedelics.. From anecdotes and
misinformation to systematic seienee. J Psythopharmacologv.
htt
ournals.sa
ub.com
doi
10.1177
02698811211069100
Neill, J. Schlag, A.K. et al. Risks and side effects associated with the use of psychedelics. In D. Nutt and Castle D. leds.)
'Psychedelics as Psychiatric Medicines" lin Pressl
Mccrone, P. Schlag A.K., Fisher, H., Neill. J., Nutt, D. A health economics analysis to investigate the cost effectiveness
of psychedelics. Lancet Psychiatry. (under Review)
SpriE8s, M, Murphy-Beiner, A, Murphy, R, Thurgur, H, Schlag, AK. ARC.. A framework for access, reciprocity and
conduct in psychedelic therapie5. Humanistic P5ychedelic5 Iunder Review)
Schlag, AK, Lynskey, M, Thurgur, H, Zafar, R, Nutt, D. et al. Psychedelic medicines.. Real World Evidence, naturalisti
studies and RCTS. Working paper
Schlag, AK, Thurgur, H, Ruffell, S et al. Reciprocity and sustainability in psychedelic medicines. Working paper
Invited conferences include.. ICPR (Amsterdaml,. MAPS IDenverl- Insight (Berlinl.. Psych Symposium (London),. Breaking
Convention (London),. Breaking Convention (Exeterl,. Exeter Philosophy of Psychedelics Research Group.

Drugscience Ltd
Trustee< report (continued)
For the year ended 30 lune 2022
Drug Science remain active lobbyists for parliamentary change both within the UK and globally. Key event5 the past year
include providing evidence to the Home Affairs Committee's inquiry into the UK'S drugs policy in May 2022 for psilocybin
rescheduling and the longstanding contribution of Prof David Nutt and Drug Science to the campaign for the Australian
government ITGAI approval of MDMA and psilocybin for treatment-resistant mental health conditions.
Following the Australian approval in February 2023, and with further discussion with the Australian charity who drove the
campaign that resulted in the policy change (Mind Med Australia), Drug Science are proposing to deliver a patient registry to
collect health outcome data as patients are prescribed both MDMA and Psilocybin in clinical settings. The registry will be
based on the UK medical cannabis registry IT211. and will be delivered in partnership with an Australian Universitv.
The Psychedelic Access and Research European Alliance IPAREAI was officially launched in lune 2022. This 15 a new initiative
spearheaded by Drug Science to act as a stand-alone, membership-led organization focusinE exclusively on the EU lobby and
streamlining EU èdvocacy activities into psychedelic science. PAREA has been very busy since their launch including their first
policy meeting on 6, December 2022 in the European Parliament, meeting with European Medicines Agency IEMAI Chief
Medical Officer ICMOI and wide-reathing press articles.
We continue to collaborate with the Canadian charity TheraPsil who support Canadians in medical need access legal.
psilocybin-assisted psychotherèpy and psilocybin. TheraPsil's Project Solace aims to streamline access via the Special Access
Programme for patients and providers and gather data on treatment outcomes. We hope to Use the findings of this research
to lobby UK regulators to make the same decision.
Enhanced Harm Reduction Workin
Grou
The Enhanced Harm Reduction Workin8 Group is a con50rtium of scientific expert5, acadernics, policy maker5, treatrnent
providers and advocacy groups, workin8 collaboratively to reduce the harm5 of intravenous drug use.
Aim
To develop the evidence base for reducing dru8-related harm by piloting a Supervised Injection Facility1SIFI in the UK
Objectives
Work with partners to establish pilot SIFS for evaluation.
Inform legal reform to enable the development of the evidence base on SIFS.
Collate and communicate the evidence-base for SIFS in reducing drug-related harm.
Provide a forum for sharing information on safe. ethical and effective provision of enhanced harm reduction services.
We believe that there is good real-world evidence for the p051tive effect5 of Supervised Injection Facilities ISIFS) across the
world.
SIFS are known by many names includinÉ Overdose Prevention Centres, and Dru@ Consumption Rooms. There are subtle
nuance5 between each, however, their function is to provide safe spaces for people to consume controlled drugs under the
supervision of people who can save lives if overdoses occur.
Our aim is to develop the evidence base for reducing drug-related harms by piloting a SIF in the UK. This collaborative
initiative will evaluate whether e5tabli5hing a SIF would prove to be c05t-effective, reduce crime, improve public health,
reduce drug litter, and increase engagement in treatment service5.
The EHR WG encourages the use of a participatory development approach in the design and development of harm reduction
seivices. Ensuring co-production in the design, development and implernentation is key to ensuring that they work, are
cornmunity-frieridly, and hold the confidente of local drug-u5ing communities. This help5 to ensure high quality, non-
judgemental service provision, acceptability and reduced stigma and the discrimination experienced by people who use
drug5.

Drugscience Ltd
Trustees, report (continued)
For the year ended 30 lune 2022
People who use drugs are sadly familiar with experiencing discrimination in health and social care setting5. As such, those
developing new services need to actively demonstrate their commitment to non-judgemental, rights-based approach and
participatory development is a good starting point. When a community owns and supports harm reduction, this ensures
effective service user recruitment, quality management and advocacy.
The Enhanced Harm Reduction Working Group IEHRWGI has brought on a Vice-chair IDr Roz Gittensl to assist the Chair IProf
Alex Stevensl. Roz Gittens also sits on the Drug Science Scientific Committee, and will be assisting Alex Stevens and James
Bunn in the operational management of this group.
The EHRWG remit ha5 expanded to cover other areas of enhanced harm reduction that are in need of further research to
demonstrate their efficacy. These two new areas of research are..
Drug Chetking- Colloquially known as 'pill testing,, this practice has been seen at festivals but also in inner cities. This
Service 15 a way to reduce the harm from drug consumption by allowing user5 to find out th8 content and purity of
5ubstance5 that they intend to consume. This enables users to make Safer choice5'. to avoid more dangerous 5ubstance5,
to use smaller quantities, and to avoid dangerous combinations.
High-Tolerance Housing IHTHI- HTH models allow people who use drugs to consume their drugs within their home. This
would usually breach a tenancy agreement. however, HTH models exisit in places such as Canada to prevent people from
being thrown out on the street following the consumption of a substante within the ctsnfines of their own home.
Supervised Injection Facilities ISIFsl- Drug Science will continue to advocate for SIFS in the UK and still intend5 on leading
a research study into their efficacy if one is able to be opened without breaching the law.
The EHRWG has not only expanded its remit, but also its membership. with new treatment providers joining the working
group in last year. These new members include..
Ana Liffey
Barod
Merchants Quay
Westminster Drugs Project
Education Worki
Grou
Our Education Working Group was setup last August and is meeting regularly and increasing in engagement and activitv.
Aim
We disseminate evidence-based drug education to students, medical professionals, academics, politicians and industry. We
strive for a world where everyone is properly informed and armed with the tools tts share their knowledge. The Working
Group effectively consolidates the educational outputs of Drug Science, which chiefly consist5 of the podcast, educational
module5, books, event5, student, univer51ty and School engagement.
Objectives
Work with partner5 to develop 5trate8ies to enga8e with educational institutions and partner with relevant network
treatment providers and organisations
Grow awareness of Drug Science and build reputation amongst educational institutions
Combat stigma in relation to drugs education within the UK educational system
Current artivitie5 include the development of a CPD module in alternative medicines with the British Association of
Psychopharmacology, development of a new Nicotine and vaping under 185 module and the continued expansion of the Dru8
Science Student Society Network ISSNI. We are currently collaborating with Prof Adam Winstock on the upcoming Students
Drug Survey, and in discussions about hosting an education conference day to be aimed at teachers and treatment
providers.Psilocybin for depression.. comparing academic vs industry-led clinical trials

Drugscience Ltd
Trustees, report (continued)
For the year ended 30 lune 2022
Dru
Science Polic
and Law journal
The Drug Science Journal continued to develop its scope of articles and remains open access to allow wide dissemination of
peer reviewed articles. Recent artitles focus on cannabis, psychedelics, the opioid epidemic in the US and wider drug harms
nd drug policies (please see.. https'.l/journals.sagepub.comlhome/d5pI. Recent publications include-.
The United Kingdom's Psychoactive Substances Act 2016. Where are we now?
Examining the gender dimension in the non-medical use of over the counter and prescription only medication
Psychedelic use predicts objective knowledee about climate change via increases in nature relatedness
A comparative study of the harms of nitrous oxide and poppers using the MCDA approach
Raising awareness.. The implementation of medical cannabi5 and psychedelics used as an adjunct to standard therapy in
the treatment of advanced metastatic breast cancer
An Interpretative Phenomenological Analysis of the use of psilocybin by veterans with symptoms of traurra
How to read a paper on the short-term impairing effects of cannabis- A selective and critical review of the literature
Comparative harms assessments for cannabis, alcohol, and tobacco.. Risk for psychosis, cognitive impairment, and traffic
accident
state naloxone co-prescribing laws show mixed effects on overdose mortality rates
Eating ourselves to death-. How food is a drug and what food abuse costs
The Mi5U5e of Drugs Regulations 2001.. A case study in poor legislative drafting
Psychedelics as potential catalyst5 of Scientific creativity and insight
The Cathinone Hydra: Increased Cathinone and caffeine adulteration in the English MDMA market after Brexit and COVID-
19 lockdowns
Farmability and pharmability.. Transforming the drug market to a health-and human rights-centred approach from self-
cultivation to safe supply of controlled substances
Regulating the oxides of nitrogen- popping the myths
Corrigendum for The risk of being culpable for or involved in a road crash after using cannabis.. A 5y5tematic review and
meta-analyse5
Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in
The Dru
Science Student Societ Network
The Drug Science Student Society Network is a student-led group that aims to provide evidence-based education on all
psychoactive substances. The group was founded in March 2020, since that time, Drug Science have established student
groups at some tsf the UK'S leading universities.
The network was relaunched as the SSN in summer 2022. It currently consists of over 20 student societies, with the majoritv
based in the UK. and a social platform (Discord) with around 150 student members. Since the start of the academic year in
September 2022, SSN events have been hosted at York, Cambridge, Barts ènd Leeds universities. with events planned over
the next three months in Manchester, Belfast, Exeter and Bristol. This year's virtual Student Psychedelic Conference will take
place in April 2023. IN line with previous years, this will be co-curated and h05ted by the students themselve5 who will
organi5e the panels, speakers and agendas over the two day5.
Dru
Science Communi
The Drug Science community has continued to grow over the last year. For the past few months, we have been working with
a fundraising consultant to be more strategic about how we use our audience data and comms channels to increase
donations. We have refreshed our Community webpage, online donation provider Ioonorboxl and membership tiers to be
clearer and more compelling.
Drug Science ran its'sentia bottle giveaway, campaign to coincide with the Christmas season and Dry January- with the main
goal of attracting new members to the Drug Science community. This ran from 5th Oecember to 31st January and resulted in
almost 150 new monthly donors giving £5 or more.
io

Drugscience Ltd
Trustees, report (continued)
For the year ended 30 lune 2022
Events
Our events offering has ramped up a gear in recent months in line with our Community push outlined above. with a particular
emphasis on engaging with students through our Student Society Network. Using university venues enables us to keep costs
down and align5 perfectly with the ethos of Drug Science a5 3 piovider of science and evidence-based drug education.
Our Street Drugs Discussion online webinar series continues to see consistently high numbers of registrations, with our
upcoming March event on Benzodiazepines reaching over 550 registrations and c.250 people expected to watch live.
Recent in-person events have included..
50 Years of Failed Drug Policy Ibook launchl- December 2022
House of Lords Evening Reception (Community eventl- December 2022
The Science tsf Psychedelics (University of Yorkl- October 2022
The Truth About Drug Science IUniver51ty of Cambridgel- january 2023
Dru85, the Media & Law (Barts Medical Schooll- Feb 2023
Podcast
In 2022, Drug Science released Season 4 of the Drug Science podcast. This was produced completely'in house, and was
downloaded 360,000 times in 2022. Over the winter break, the host of the podcast Iprof David Nuttl was unable to record
regular episodes, so we took a temporary break from recording the show. In early 2023, we started recording brand new
episodes and released the first episode of Season 4 on March 1, 2023, releasing new episodes fortni@htly for the next 12
months.
To ensure that we can be flexible with our episode recording schedule, we have enlisted two'co-hosts, of the podcast- Dr
Hannah Thurgur (Drug Science staff) and Professor Jo Neill Ichair of the Medical Psychedelics Working Group).
FINANCIAL REVIEW
Result for the year
The results for the year are shown in the statement of the financial aetivities on page 13. During the year, the tharity reteived
donations and other income totallin8 of £998,76612021= £621,633). The cost of rai5in8 fund5 for the period lincluding
allocated support costs) totalled £135,59812021= £102,909). Expenditure on charitable activities of £556,37212021..
£449,423) brought total expenditure for the year to £691,97012021'. £552,332). The result for the year ended 30 June 2022
was a surplus of £306,796 (surplus 2021.. £69,301).
The balance of the unrestricted re5etve5 a5 at 30 June 2022 was £337,67512021.. £217,831) and restricted reserves £264,265
12021.. £77,313).
Reserves policy
The level of reserves is monitored and reviewed by the trustees at least annually. The trustees believe that the charity should
target to hold unrestricted financial reserves equivalent to a minimum of 2 year's core costs. This is estimated to be
£160,000.
As 3t 30 June 2022, the charity'5 unrestricted reserves wa5 £337,67512021= £217,831) of which an arnount of £180,000 has
been designated to be Spent on the PET-MRI Synaptogenesis study with DMT within the department of Brain Sciences at
Imperial College London. The free reserves was £157, 67512021.. £217,831). This is in line with the estimate stated above.
The trustees believe that current level of reserves is sufficient to cover the core costs of the organisation. ensuring financial
stability in the event of unplanned adverse circumstances.
li

Drugscience Ltd
Trustees, report {continued)
For the year ended 30 June 2022
Going concern
After making appropriate enquiries, the trustees have a reasonable expectation that the charity has adequate resources to
continue in operational existence for the foreseeable future. For this rea50n, they continue to adopt the goin8 concern basis
in preparing the financial statements.
Plans for future years
The priority for the charity over the last four years has been to secure financial stability. This airn has now been largely
achieved. with unrestricted reserves now exceeding the general reserve policy, ensuring that the organisation is in a strong
position. The aim for the foreseeable future is to maintain financial sustainability, ensurine that its income is sufficient to
allow the organisation to continue to meet its charitable objectives.
12

Drugscience Ltd
Trustees, report {continued)
For the year ended 30 June 2022
Trustees, responsibilities statement
The trustees Iwho are also directors of the charity for the purposes of company lawl are responsible for
preparing the Trustees, report and the financial statements in accordance with applicable law and United
Kingdom Accounting Standards Iunited Kingdom Generally Accepted Accounting Practice).
Company law requires the trustees to prepare financial statements for each financial year. Under company law
the trustees must not approve the financial 5tatement5 unle55 they are satisfied that they give a true and fair
view of the State of affairs of the charity and income and expenditure of the charity foi the year.
In preparing these financial Statements, the trustees are required to..
select suitable accounting policies and then apply them consistently..
observe the methods and principles in Accounting and Reportin8 by Charities.. Statement of
Recommended Practice applicable to charities preparing their accounts in accordance with 'the
Financial ReportinE Standard applicable to the UK and Republic of Ireland. I'FRS 102,1,.
makejudgements and accounting e5timate5 that are reasonable and prudent.,
state whether applicable United Kingdom Accounting Standards have been followed, subject to any
material departure5 di%t105ed and explained in the financial statements,. and
prepare the financial statements on the going concern basis unless it is appropriate to presume that the
trust will continue in operation.
The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain
the charity's transactions and disclose with reasonable accuracy at any time the financial position of the
charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They
re also responsible for Safeguarding the asset5 of the the charity and henee for taking reasonable steps for the
prevention and detection of fraud and other irregularities.
The trustees are responsible for the maintenance and integrity of the corporate and financial information
included on the charity's website. Legislation in the United Kingdom governing the preparation and
dissemination of financial statements may differ from legislation in other jurisdictions.
This report was approved by the trustees and signed on their behalf bv..
Prof Ilana Crome
Chair
Date.. 2510412023
13

Drugscience Ltd
Buzzacott
Independent examinerfs report tothe trustees of Drugscience Ltd
For the year ended 30 June 2022
Independent examiner's report to the trusteesof Dru8science Ltd I'the chariv)
I report to the trustees on my examination of the financial statements of the charity for the year ended 30June 2022.
Responsibilities of basis of reports
As the trustees of the charity land also its directors for the purposes of company lawl you are responsible for the
preparation of the financial 5tatement5 in accordance with the requirements of the Companies Act 20061'the 2006 Act'l.
Having sat15fied myself that thefinancial statement5 of the charity are not required to be audited under Part 16 of the 2006 Act
and are eligible for independent examination, I report in respect of my examination of your charity's financial statements
as carried out under section 145 of the Charities Act 20111'the 2011 Act'l. In carrying out my examination I have followed
th8 directions given by the Charity Cornmi55ion under section 14515llbl of the 2011 Act.
Independent examiner's statement
I have completed my examination. I confirm that no rnatters have come to myattention in connection with my examination
giving me cause to believe..
accounting record5 were not kept in respect of the charity as required by section 386 of the 2006 Act,. or
the financial statements do not accord with those record5,' or
the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act otherthan any
requirement that the financial statements give a 'true and fair view, which is not a matter considered as part of an
independent examination; or
the financial statements have not been prepared in accordance with the methods and principles of the for
"Accounting and Reporting by Charities-. the Statement of Recommended Practice applicable to charities preparing
their account5 in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS
1021 (effective l January 20151."
I h3ve no concerns and have come acr055 no other matters in connection with the examination to which attention should be
drawn in this report in order to enable a proper understanding of the accounts to be reached.
Gumayel Miah, ACA
Buzzacott LLP
Chartered Accountants
130 Wood Street
London
EC2V 6DL
Date.. 27 April 2023
14

Drugscience Ltd
Statement of financial activities
For the year ended 30 June 2022
2022
Unrestrlcted
Restrlcted
Total
funds
funds
funds
Note
2022
2022
2022
Income from..
Donations & legacies
Charitable activities
416,695
9.691
426,386
572,380
989,075
9.691
998,766
Total income
572,380
Expendlture on:
Raisingfunds
Charitable activities
48,204
258,338
306,542
87,394
298,034
385.428
135.598
556,372
Total expenditure
691.970
Net incomellexpenditurel and
net movement in funds
119,844
186,952
306,796
Reconciliation of funds:
Total funds at 30 June 2021
217,831
77,313
295,144
Total funds at 30June 2022
14
337,675
264.265
601.940
15

Drugscience Ltd
Statement of financial activities
Foi the year ended 30 June 2021
2021
Unrestricted
Restricted
Total
funds
funds
funds
Note
2021
2021
2021
Income from..
Donations & legacies
Charitable activities
283,109
21,440
304,549
317,084
600,193
21,440
621,633
Total income
317,084
Expenditure on..
Rai5in£ fund5
Charitable activities
33,114
179,962
69,795
269,461
102,909
449.423
Total expenditure
213,076
339,256
552,332
Net incomellexpenditurel and net
movement in funds
91,473
122,1721
69,301
Reconciliation of funds..
Total funds at 30June 2020
126,358
99,485
225,843
Total funds at 30 June 2021
14
217,831
77,313
295,144
The Statement of financial activities includes all gains and losses recognised in the year.
All of the charity's activities derived from continuing operations during the above two financial periods. The
note5 on pages 18 to 25 form part of these financial statements.
16

Drugsclence Ltd- Registered company number: 08032149
Statement of financial position
For the year ended 30 June 2022
2022
2021
Note
Investments
li
Current assets
Debtors
Cash at bank and in hand
12
176,380
681.457
857.837
104.181
341,259
445.440
Creditors: Amounts falling due within one
year
13
12SS.8981
1150,2961
Net current a55ets
601,939
295,144
Total assets less turrent liabilities
601,940
295,144
Total net assets
601,940
295,144
Charlty funds
14
Unrestricted funds=
General fund
Designated funds
157.675
180,000
217,831
337.675
264,265
601,940
217,831
77,313
295,144
Restricted funds
Total funds
15
The trustees consider that the charity is entitled to exemption from the requirement to have an audit under the
provision5 of section 477 of the Companies Act 20061.the ACV'I and mernber5 have not required the charity to obtain
an audit for the year in question in accordance with section 476 of the Act.
The trustees acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with
respect to accounting records and for preparing financial statements which give a true and fair view of the state of
affairs of the charitable company a5 at 30June 2022 and of its income and expenditure for the year in accordance with
the requirements of 5ectiOn5 394 and 395 of the Act and which otherwise cornply with the requirements of the
Companies Act 2006 relating to financial statements, so far as applicable to the charity.
The financial statements have been prepared in accordance with the special provisions applicable to small companies
within Part 15 of the Companies Act 2006 and in accordance with FRS 102.
The financial statements were approved by the trustees on 2510412023 and signed on their behalf by..
Prof Ilana Crome
Chalr
The notes on pages 18 to 25 form part of these financial statements.
17

Drugscience Ltd
Notes to the financial statements
For the year ended 30 June 2022
General information
Drugscience Ltd I'the charity'l is a private company limited by guarantee and is incorporated in England and Wales.
The members of the charity are the tru5tee5 named on page l. In the event of the charity being wound up, the
liability in respett of the guarantee 15 limited to £1 per rnember of the charity. It5 registered office is 130 Wood
Street, London, England, EC2V 6DL. The company registration number is 08032149 and the charity number 15
1150449.
Accountlng Pollcles
Basis of preparation of financial statement5
The financial statements have been prepared under the historical cost convention. The financial statements have
been prepared in accordance with the Statement of Recommended Prattice applicable to charities preparing their
accounts in accordance with the financial reporting standard applicable in the United Kingdom and Republic of
Ireland IFRS 1021 (Charities SORP IFRS 1021" The financial reporting standard applicable in the UK and Republic of
Ireland I'FRS, 1021, and the Charitie5 Act 2011.
The charity continues a public benefit entity as defined by FRS 102. The financial statements are presented in
During the year ended 30 June 2022, the charity invested in a wholly owned trading subsidiary, Drugscience
Trading Ltd and further details are provided at note 11. The result5 of the 5ub5idiary have not been consolidated in
these financial statements as they have not been material to the activities of the parent charity.
ssessment of going Con￿rn
The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these
accounts. The trustees have made this assessment in respect to a period of one year from the date of approval of
these accounts.
The trustees of the charity have concluded that there are no material uncertainties related to events or
conditions that may cast significant doubt on the ability of the charity to continue as a going concern. The
trustees are of the opinion that the charity will have sufficient resources to meet its liabilities as they fall due.
2.3 Cash flow statement
The financial statements do not include a cash flow statement because the charity, as a small reporting entity, is
exempt from the requirement to produce such a 5tatemeNt under AccouNtin8 and Reporting by charities
Statement of Recommended Practice Icharities SORP IFRS 10211.
Fund accountlng
The general fund is an unrestricted fund which is available for use at the discretion of the trustees in fvrtherance
of the general objectives of the charity which has not been designated for other purposes.
The desiEnated fund of £180,(XJO is an unrestricted fund which is set aside to be spent on the PET-MRI
Synaptogenesi5 Study with DMT within the department of Brain Science at Imperial College London.
The restricted fund relates to grants used to cover associated projects costs as specified by the grant provider.
18

Drugscience Ltd
Notes to the financial statements (continued)
For the year ended 30 lune 2022
Income
Income is recognised in the period in which the charity is entitled to receipt, the amount can be measured ieliably
and it Is probable that income will be received. Where incorne relates to future periods, this income will be deferred.
Grants and donations received for the general purposes of the charitable company are included as unrestricted funds-
grants and donations for activities restricted by the wishes of the donor are taken to restricted funds.
Expendlture
Liabilities are recogni5ed a5 expenditure a5 soon a5 there is a legal or con5tructwe obligation committing the charity to
make a payment to a third party or it is probable that a transfer of economic benefit5 will be required in settlement
and the amount of the obligation can be measured reliably. All expenditure is stated exclusive of VAT.
Expenditure is included in the accounts on an accruals basis and includes attributable VAT, which cannot be
recovered.
Expenditure is allocated to the particular activity on a direct basis or by allocation based on the level of direct
expenditure relating to that activitv.
Expenditure comprises the following..
. The costs of charitable activities comprise expenditure related to the charity's primary charitable purposes. Such
costs include..
General overhead costs
Related support costs
b. The cost of raising funds comprises expenditure related to the charity, expenses in relation to raising funds for
the charity. Such costs include..
Direct costs
Related support costs
c. Support costs are the costs associated with the governance arrangements of the charity and the general running
of the charity. Included within this category are costs associated with the strategic management of the
charity's activities as opposed to day-to-day management. Support Costs are allocated on the basis of time
spent of these activitie5.
Dèbtors
Trade and other debtors are recognised at the settlement amount after any trade discount offered and net of any
provision. Prepayments are valued at the net amount prepaid.
Cash at bank and in hand
Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three
months or less from the date of acquisition or opening of the deposit or similar account.
Liabilities and provisions
Liabilities are recognised when there is an obligation at the reporting date as a result of a past event, it is probable
that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be
estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or
the amount it has received as advanced payment5 for the goods or services it must provide.
19

Drugscience Ltd
Notes to the financial statements (continued)
For the year ended 30 June 2022
Donatlons & legacles
2022
Unrestrictèd
Rèstritted
Total
2022
2022
2022
Donations
59,336
59,336
Educational grants
357.359
572.380
929,739
416.695
572,380
989,075
2021
Unrestricted
Restricted
Total
2021
2021
2021
Donations
26,669
26,669
Educational grants
256,440
283,109
317,084
317,084
573,254
600,193
Dèfèrred incomèanalysis
Unrestricted
Restrlcted
Total
funds
funds
funds
Balance as at 01 july 2021
Intome deferred in the current year
38.333
38.333
32,791
97,721
130,512
Amount released from previous year
Balance a5 at 30 June 2022
138,3331
97,721
138,3331
130,512
32,791
Note.. Donations deferred during the year is related to educational grants received in the year for future periods.
20

Drugscience Ltd
Notes to the financial statements (continued)
For the year ended 30 lune 2022
Income from charitable artivities
2022
Unrestricted
2022
Restricted
2022
Total
2022
Book Royalties
5.360
5.360
Events
4.331
4.331
Non-profit income
9.691
9.691
2021
Unrestricted
2021
Restricted
2021
Total
2021
Book Royalties
5,800
5,800
Events
4,928
4,928
Non-profit income
10,712
10,712
21,440
21,440
Ralslng funds
2022
Unrestrlcted
Restr5cted
Total
2022
2022
2022
Allocated 5UPPOrt costs (note 71
Marketing
PR/Public income
43.694
252
52.593
31,863
96.287
32,115
4,258
2,938
7,196
48,204
87.394
135,598
2021
Unrestricted
Restricted
Total
2021
2021
2021
Allocated support costs (note 71
Marketing
PR/Public income
29,619
1,168
47,552
17,368
77,171
18,536
2,327
4,875
7,202
33,114
69,795
102,909
21

Drugscience Ltd
Notes to the financial statements (continued)
For the year ended 30 June 2022
Expendlture on charltable actlvltles
2022
Unrestricted
Restricted
Totsl
2022
2022
2022
Allocated support costs (note 71
258.338
298,034
556,372
258.338
298,034
556,372
2021
Unrestricted
2021
Restricted
2021
Total
2021
Allocated support costs (note 71
179,962
269.461
449,423
179,962
269.461
449,423
Support costs
2022
Raising
fund5
(note 51
Charitable
activities
Total
fund5
Untsstncted
Aunds
Rtstrirted
fvnds
(notè 61
Staff costs
63.919
362,201
426,120
195.786
230,334
Transport costs
970
5,500
6A170
3,396
3,074
Governance costs
Inote 101
other support costs
10,741
10,741
10.741
31,398
177,930
209,328
84.469
124,859
Total
96.287
556,372
652,659
294.392
358,267
2021
Raising
funds
(note 51
Charitable
Total
funds
Unrestricted
funds
Restrirted
funds
Inote 61
Staff costs
53,332
302,212
355.544
148,516
207,028
Transport costs
31
178
209
15
Governance c05tS
Inote 101
Other support costs
12,120
12,120
12,120
23,808
134,913
158,721
48,927
109,794
Total
77,171
449,423
526,594
209,578
317,016
8. Trustees, remunerat5on
No trustees received any emoluments or r￿mbUrseMent of outof pocket expenses for their services as trustees during the
year12021.' none).
22

Drugscience Ltd
Notes to the financial statements (continued)
For the year ended 30 lune 2022
Staff costs
2022
2021
Wages and salaries
Social security cost5
Other pension costs
Freelance staff
324,819
23,898
6,653
70,750
426,120
244,940
23,513
4,976
82,115
355,544
The average monthly number of employees during the year was 912021.. 51.
Staff receiving emoluments in excess of £60,000, excludin8 employer pension contributions, during the year were as
follows:
2022
No.
2021
No.
£60,WI-£70,000
10. Governance costs
2022
2021
Accountancy fee
Independent examination
8.890
1,851
10,741
10,270
1,850
12,120
11. Flxed asset Investments
Investments
In subsidiary
Companies
At lJuly2021
Addition during the year
At 30 June 2022
Subsidiary undertakin8
The following was a subsidiary undertaking of the charity..
Name
Countryof
incorporation
England and Wales
Clas5 of shares
Holding
Orugscience Trading Ltd
Ordinarv
loo%
23

Drugscience Ltd
Notes to the financial statements (continued)
For the year ended 30 lune 2022
12. Debtors
2022
2021
Trade debtors
Other debtor5
176,380
103.973
208
104,181
176,380
13. Credltors: amounts falllng due wlth5n one year
Total
2022
Total
2021
Trade creditors
Arnount owed to group undertakin8 (note 161
Other creditor5
Accruals
Deferred income
Other taxation
34,478
65,081
2,837
5,017
130,512
17,973
255,898
28,186
38,353
5,017
38,333
40,407
150,296
14. Analysis of net assets between funds
2022
Restricted
funds
Unrèstrirted funds
Total funds
Investments
Current assets
361,985
197,7211
264,265
495,852
1158,1771
337,675
857,837
1255.8981
601,940
2021
Re5tiicted
fund5
Unrestricted funds
Total fund5
Current assets
115,646
138,3331
77,313
329,794
1111,9631
217,831
445,440
1150,2961
295,144
24

Drugscience Ltd
Notes to the financial statements (continued)
For the year ended 30 June 2022
15. Restrirted funds analysis
As at l July
2021
Income
Expendlture
Transfers
Asat30
June 2022
Twenty21 lal
PAREA Ibl
Long Covid Icl
77,313
501,667
25,713
45,000
1314,9601
125,7131
144,7551
264,020
245
Total restrirted
77,313
572,380
1385,4281
264,265
Asat lJuly
2020
A5at30
June 2021
Income
Expenditure
Transfers
Twenty21 lal
99,485
317,084
1339,2501
77.313
Total restricted
99,485
317,084
1339,2501
77.313
al The Twenty21 fund represents the income which was used to create the UK'S largest body of evidence for
the effectiveness and tolerability of medical cannabis. The charity hope that the findings of Project Twenty21
will provide evidence for NHS funding where the benefit5 of treatment with medicinal cannabis is proven to
outweigh the potential risks.
bl PAREA fund represents the income which was used to raise awareness, provide evidence-ba5ed policv
recommendations and accelerate scientific and policy response, leading to the adoption of a holistic approach
to psychedelic novel treatments in Europe.
Long Covid represent5 the income which was used to test high cannabidiol ICBDI coNtainin8 medical cannabis
oil to see if it can improve the symptoms of Long COVID.
16. Related party transactions
During the year ended 30 June 2022, the charity provided a loan of £65,08112021= Nil) to Drugscience Trading Ltd, a
wholly owned subsidiary. At 30 June 2022, the amount due to this company was £65.08112021.. Nill. This loan is interest
free and repayable on demand.
There were no other related party transactions in the period of report12021- none).
25